Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antithymocyte globulin + rituximab + mycophenolate mofetil + tacrolimus
- Development stage
- Preclinical
- Lead developer
- IDEC
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination immunosuppressive therapy consisting of antithymocyte globulin (ATG), rituximab, mycophenolate mofetil, and tacrolimus. This regimen targets multiple components of the immune system: ATG depletes T cells, rituximab targets B cells by binding to CD20, mycophenolate mofetil inhibits inosine monophosphate dehydrogenase to prevent lymphocyte proliferation, and tacrolimus inhibits calcineurin to prevent T-cell activation. The combination provides comprehensive immunosuppression used primarily in transplantation medicine to prevent graft rejection and graft-versus-host disease, as well as in the treatment of certain autoimmune conditions.
- Brand names
- RituxanPrografCellCeptThymoglobulin
- Other names
- ATG + rituximab + mycophenolate mofetil + tacrolimus
02
Targets
Beyond the preview
Go deeper on antithymocyte globulin + rituximab + mycophenolate mofetil + tacrolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antithymocyte globulin + rituximab + mycophenolate mofetil + tacrolimus.